The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension-Reference-Cited by-同舟云学术

The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension

Published:2015-01-13 Issue:19 Volume:11 Page:2291-2304
ISSN:1613-6810
Container-title:Small
language:en
Short-container-title:Small

Author:

Duong Hien T. T.¹,Dong Zhixia²³,Su Lin²,Boyer Cyrille¹,George Jacob²,Davis Thomas P.⁴⁵,Wang Jianhua²

Affiliation:

1. Australian Centre for Nanomedicine and Centre for Advanced Macromolecular Design; School of Chemical Engineering; University of New South Wales; Sydney 2052 Australia

2. Storr Liver Unit; Westmead Millenium Institute and Westmead Hospital; University of Sydney; Sydney NSW Australia

3. Shanghai First People's hospital; School of Medicine; Shanghai Jiaotong University; China

4. ARC Centre of Excellence in Convergent Bio-Nano Science & Technology; Monash Institute of Pharmaceutical Sciences; Monash University; Parkville Melbourne VIC 3052 Australia

5. Department of Chemistry; University of Warwick; Coventry UK

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/smll.201402870/fullpdf

Reference52 articles.

1. Nitric Oxide: A Physiologic Mediator of Penile Erection

2. NO Parkin in Parkinson's Disease

3. Nitric Oxide: First in a New Class of Neurotransmitters

4. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus

5. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

2. Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems;ACS Nano;2024-07-31

3. Pathophysiology and therapeutic options for cirrhotic portal hypertension;The Lancet Gastroenterology & Hepatology;2024-07

4. Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis;Journal of Controlled Release;2024-04

5. The role and mechanism of hydrogen sulfide in liver fibrosis;Nitric Oxide;2024-04